"scientific article published on 01 July 1997"@en . "57" . "\u043D\u0430\u0443\u043A\u043E\u0432\u0430 \u0441\u0442\u0430\u0442\u0442\u044F, \u043E\u043F\u0443\u0431\u043B\u0456\u043A\u043E\u0432\u0430\u043D\u0430 \u0432 \u043B\u0438\u043F\u043D\u0456 1997"@uk . . . . . "A.S. L\u00FCbbe et al., Preclinical experiences with magnetic drug targeting: tolerance and efficacy. Cancer Res., 56: 4694-4701, 1996; and Clinical experiences with magnetic drug targeting: a phase I study with 4'-epidoxorubicin in 14 patients with adva"@nl . "A.S. L\u00FCbbe et al., Preclinical experiences with magnetic drug targeting: tolerance and efficacy. Cancer Res., 56: 4694-4701, 1996; and Clinical experiences with magnetic drug targeting: a phase I study with 4'-epidoxorubicin in 14 patients with advanced solid tumors. Cancer Res., 56: 4686-4693, 1996"@en . "im Juli 1997 ver\u00F6ffentlichter wissenschaftlicher Artikel"@de . "A.S. L\u00FCbbe et al., Preclinical experiences with magnetic drug targeting: tolerance and efficacy. Cancer Res., 56: 4694-4701, 1996; and Clinical experiences with magnetic drug targeting: a phase I study with 4'-epidoxorubicin in 14 patients with adva"@en . "A.S. L\u00FCbbe et al., Preclinical experiences with magnetic drug targeting: tolerance and efficacy. Cancer Res., 56: 4694-4701, 1996; and Clinical experiences with magnetic drug targeting: a phase I study with 4'-epidoxorubicin in 14 patients with adva"@nl . "Gallo JM" . . "A.S. L\u00FCbbe et al., Preclinical experiences with magnetic drug targeting: tolerance and efficacy. Cancer Res., 56: 4694-4701, 1996; and Clinical experiences with magnetic drug targeting: a phase I study with 4'-epidoxorubicin in 14 patients with adva"@en . "A.S. L\u00FCbbe et al., Preclinical experiences with magnetic drug targeting: tolerance and efficacy. Cancer Res., 56: 4694-4701, 1996; and Clinical experiences with magnetic drug targeting: a phase I study with 4'-epidoxorubicin in 14 patients with adva"@nl . . "A.S. L\u00FCbbe et al., Preclinical experiences with magnetic drug targeting: tolerance and efficacy. Cancer Res., 56: 4694-4701, 1996; and Clinical experiences with magnetic drug targeting: a phase I study with 4'-epidoxorubicin in 14 patients with adva"@en . . . . . "9230223" . "1997-07-01T00:00:00Z"^^ . . . . "art\u00EDculu cient\u00EDficu espubliz\u00E1u en xunetu de 1997"@ast . "3063-3065" . "wetenschappelijk artikel"@nl . "14" . . .